Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study

Type 2 diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis. Current international guidelines recommend the use of noninvasive tests as initial assessments for NAFLD, but the role of noninvasive tests as monitoring tools has not been established. We aimed to study the role of transient elastography as a monitoring tool in patients with type 2 diabetes.

[1]  Myeong Jun Song,et al.  Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[3]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  V. Wong,et al.  Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease , 2019, Gut.

[5]  V. Wong,et al.  Repeating measurements by transient elastography in non‐alcoholic fatty liver disease patients with high liver stiffness , 2018, Journal of gastroenterology and hepatology.

[6]  R. Andrade,et al.  The effects of metabolic status on non‐alcoholic fatty liver disease‐related outcomes, beyond the presence of obesity , 2018, Alimentary pharmacology & therapeutics.

[7]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[8]  V. de Lédinghen,et al.  Noninvasive biomarkers in NAFLD and NASH — current progress and future promise , 2018, Nature Reviews Gastroenterology & Hepatology.

[9]  V. Wong,et al.  A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis , 2018, Hepatology.

[10]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[11]  V. Wong,et al.  Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.

[12]  V. Wong,et al.  Prognostic Value of Controlled Attenuation Parameter by Transient Elastography , 2017, The American Journal of Gastroenterology.

[13]  V. Wong,et al.  Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. , 2017, Journal of hepatology.

[14]  M. Kumar,et al.  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. , 2017, Journal of hepatology.

[15]  V. Wong,et al.  Application of the combined FibroMeter vibration‐controlled transient elastography algorithm in Chinese patients with non‐alcoholic fatty liver disease , 2016, Journal of gastroenterology and hepatology.

[16]  Julien Vergniol,et al.  Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[17]  Jun Yu,et al.  Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. , 2016, The lancet. Gastroenterology & hepatology.

[18]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[19]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[20]  R. Franchis.  Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension , 2015 .

[21]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[22]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[23]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[24]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  A. McCullough,et al.  Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis , 2015, Journal of clinical gastroenterology.

[26]  R. de Franchis.  Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. , 2015, Journal of hepatology.

[27]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[28]  G. Farrell,et al.  Postprandial hyperinsulinemia is universal in non‐diabetic patients with nonalcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[29]  V. Wong,et al.  On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients , 2011, Antiviral therapy.

[30]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[31]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[32]  F. Chan,et al.  Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[33]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .